Related Experiment Video

Updated: Jan 10, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the

Jacob Sands1, Myung-Ju Ahn2

  • 1aLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Future Oncology (London, England)
|November 21, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Dato-DXdDatopotamab deruxtecanNon-small cell lung cancerPlain language summary publicationTROPION-Lung01

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.9K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.9K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025.

Cancer·2026

T-cell engagers in small cell lung cancer.

Cancer·2026

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026

A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer.

bioRxiv : the preprint server for biology·2026

Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

Future oncology (London, England)·2026

Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology.

Future oncology (London, England)·2026

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

Future oncology (London, England)·2026

DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.

Future oncology (London, England)·2026

STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.

Future oncology (London, England)·2026

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Future oncology (London, England)·2026

Geospatial approaches to analysing spatial patterns of stroke incidence and mortality: a systematic review.

Geospatial health·2026

Trial and error: a mapping review of operative and perioperative strategies to reduce post-appendicectomy abdominal infection.

Annals of the Royal College of Surgeons of England·2026

Telemedicine for cardiometabolic disease control in Latin America and the Caribbean: A systematic review and meta-analysis.

Preventive medicine reports·2026

Supraglottic airway versus endotracheal intubation in out-of-hospital cardiac arrest: a systematic review and meta-analysis.

Resuscitation plus·2026

Patient-attributed lunar periodicity in probable ulcerated erythema nodosum leprosum: A case report and proposed psychoneuroendocrine mechanism.

IDCases·2026

Vitamin D Deficiency, Inflammatory Biomarkers, and MASLD in Older Adults with Type 2 Diabetes: A Cross-Sectional Study.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us